|
Apr 15
|
Bristol Myers stumbles in bid to widen heart drug’s use
|
|
Apr 3
|
Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial
|
|
Apr 3
|
Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says
|
|
Apr 2
|
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
|
|
Apr 2
|
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'
|
|
Apr 2
|
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
|
|
Apr 2
|
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)
|
|
Mar 11
|
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
|
|
Mar 3
|
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
|
|
Feb 19
|
Should You Invest in Edgewise Therapeutics (EWTX)?
|
|
Oct 1
|
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
|
|
May 10
|
Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results
|
|
May 10
|
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
|
|
May 9
|
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
May 7
|
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
|
|
May 7
|
Edgewise Therapeutics doses first subject in HCM drug trial
|
|
May 6
|
Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
|
|
Apr 23
|
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
|
|
Apr 15
|
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
|
|
Mar 28
|
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
|